ZEVRA THERAPEUTICS, INC. (ZVRA) 8-K Current Report: March 16, 2026
Filed: March 16, 2026
Health Care
Pharmaceutical PreparationsZEVRA THERAPEUTICS, INC. (ZVRA) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 1.02: Termination of a Material Definitive Agreement
- Item 7.01: Regulation FD Disclosure
ZEVRA THERAPEUTICS, INC. 8-K Mar 16, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Zevra sells entire SDX portfolio (AZSTARYS/KP415, KP1077) to Commave for $50M total cash — deal closed March 13, 2026
- • Payment structure: $25M at signing, $20M within ~10 business days, $5M upon delivery of manufacturing/patent records
- • Full termination of 2019 AZSTARYS License Agreement and mutual release of all claims — resolves Delaware Chancery Court litigation (C.A. No. 2024-0920)
- • Zevra retains underlying SDX patents/know-how but grants Commave a worldwide, royalty-free, perpetual, irrevocable license — no future royalty stream from SDX assets
- • Represents a complete exit from the SDX/AZSTARYS franchise; investors should assess what revenue or pipeline value, if any, is lost vs. $50M cash infusion
Item 1.02 · Termination of a Material Definitive Agreement
- • Full repayment of $63.0M outstanding principal (including ~$3.0M accrued PIK interest) plus cash interest on March 12, 2026
- • Original facility: $100.0M senior secured, $60.0M drawn at inception (April 2024); early repayment ~3 years ahead of April 2029 maturity
- • All liens on substantially all company and subsidiary assets now released — balance sheet fully unencumbered
- • Lenders HCR Stafford, HCR Potomac, and Perceptive Credit fully exited; eliminates restrictive covenants typically tied to such credit agreements
Item 7.01 · Regulation FD Disclosure
- • Zevra Therapeutics issued a press release March 16, 2026 announcing an unspecified "Agreement" — full details in Exhibit 99.1
- • Nature and financial terms of the Agreement not disclosed in this item; investors should review Exhibit 99.1 for deal specifics
- • Reg FD disclosure signals material agreement deemed significant enough to require broad simultaneous public dissemination
Other ZEVRA THERAPEUTICS, INC. 8-K Filings
Get deeper insights on ZEVRA THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.